Since BIM deletion polymorphism is germline genetic event and we did not observe significant association between BIM deletion polymorphism and other clinicopathological factors except age, we suggest that BIM deletion polymorphism may mediate the cancer initiation rather than tumor progression in human mammary gland. The gene discussed is BCL2L11; the disease is cancer.